
Pfizer and Medivation have written off their Alzheimer’s candidate dimebon after another Phase III failure. The firms said a 12-month …

Despite many years of relentless research efforts, Alzheimer’s disease, the most common form of dementia, remains impossible to cure. According …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

